Stock Scorecard
Stock Summary for Takeda Pharmaceutical Company (TAK) - $15.05 as of 3/28/2025 9:07:17 PM EST
Total Score
14 out of 30
Safety Score
52 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for TAK
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for TAK
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for TAK
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for TAK
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for TAK (52 out of 100)
| Stock Price Rating (Max of 10) | 6 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 10 |
| Book Value to Price (Max of 10) | 10 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 6 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 8 |
| Price to Earnings (Max of 10) | 5 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for TAK
Financial Details for TAK
Company Overview |
|
|---|---|
| Ticker | TAK |
| Company Name | Takeda Pharmaceutical Company |
| Country | USA |
| Description | Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 12/31/2024 |
| Next Earnings Date | 5/7/2025 |
Stock Price History |
|
| Last Day Price | 15.05 |
| Price 4 Years Ago | 11.97 |
| Last Day Price Updated | 3/28/2025 9:07:17 PM EST |
| Last Day Volume | 935,361 |
| Average Daily Volume | 1,533,477 |
| 52-Week High | 15.30 |
| 52-Week Low | 12.29 |
| Last Price to 52 Week Low | 22.46% |
Valuation Measures |
|
| Trailing PE | 35.21 |
| Industry PE | 37.01 |
| Sector PE | 40.10 |
| 5-Year Average PE | 8.28 |
| Free Cash Flow Ratio | 0.10 |
| Industry Free Cash Flow Ratio | 11.91 |
| Sector Free Cash Flow Ratio | 47.05 |
| Current Ratio Most Recent Quarter | 1.31 |
| Total Cash Per Share | 156.39 |
| Book Value Per Share Most Recent Quarter | 4,679.77 |
| Price to Book Ratio | 0.97 |
| Industry Price to Book Ratio | 8.86 |
| Sector Price to Book Ratio | 21.92 |
| Price to Sales Ratio Twelve Trailing Months | 0.01 |
| Industry Price to Sales Ratio Twelve Trailing Months | 88.85 |
| Sector Price to Sales Ratio Twelve Trailing Months | 27.78 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 3,159,600,000 |
| Market Capitalization | 47,551,980,000 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | 9/30/2024 |
| Previous Dividend Amount | 0.2922 |
| Current Dividend Amount | 0.3261 |
| Total Years Dividend Increasing | 0 |
| Trailing Annual Dividend Rate | 0.62 |
| Trailing Annual Dividend Yield | 4.11% |
| Forward Annual Dividend Rate | 0.65 |
| Forward Annual Dividend Yield | 4.34% |
| 5-Year Dividend Payments Count | 10 |
| 3-Year Average Dividend Yield | 4.62% |
| 5-Year Average Dividend Yield | 5.20% |
| 1-Year Dividend Growth Rate Percentage | -1.71% |
| 3-Year Dividend Growth Rate Percentage | -3.18% |
| 5-Year Dividend Growth Rate Percentage | -7.64% |
| All-Time Dividend Growth Rate Percentage | -3.37% |
| Dividend Payout Ratio | 143.79% |
Income Statement |
|
| Quarterly Earnings Growth YOY | -77.70% |
| Annual Earnings Growth | -54.56% |
| Reported EPS 12 Trailing Months | 0.43 |
| Reported EPS Past Year | 29.31 |
| Reported EPS Prior Year | 18.49 |
| Net Income Twelve Trailing Months | 208,065,000,000 |
| Net Income Past Year | 144,067,000,000 |
| Net Income Prior Year | 317,017,000,000 |
| Quarterly Revenue Growth YOY | 3.00% |
| 5-Year Revenue Growth | 15.25% |
| Operating Margin Twelve Trailing Months | 0.53% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 494,126,000,000 |
| Total Cash Past Year | 457,800,000,000 |
| Total Cash Prior Year | 533,530,000,000 |
| Net Cash Position Most Recent Quarter | -4,210,555,000,000 |
| Net Cash Position Past Year | -4,018,701,000,000 |
| Long Term Debt Past Year | 4,476,501,000,000 |
| Long Term Debt Prior Year | 4,042,741,000,000 |
| Total Debt Most Recent Quarter | 4,704,681,000,000 |
| Equity to Debt Ratio Past Year | 0.62 |
| Equity to Debt Ratio Most Recent Quarter | 0.61 |
| Total Stockholder Equity Past Year | 7,273,264,000,000 |
| Total Stockholder Equity Prior Year | 6,354,122,000,000 |
| Total Stockholder Equity Most Recent Quarter | 7,418,274,000,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 766,356,000,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 242.55 |
| Free Cash Flow Past Year | 235,614,000,000 |
| Free Cash Flow Prior Year | 343,467,000,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.36 |
| MACD Signal | 0.37 |
| 20-Day Bollinger Lower Band | 12.34 |
| 20-Day Bollinger Middle Band | 13.72 |
| 20-Day Bollinger Upper Band | 15.09 |
| Beta | 0.41 |
| RSI | 73.35 |
| 50-Day SMA | 13.56 |
| 150-Day SMA | 13.71 |
| 200-Day SMA | 13.66 |
System |
|
| Modified | 3/28/2025 8:43:48 AM EST |